Management of severe hidradenitis suppurativa with biologic therapy and wide excision

• Published in: Archives of plastic surgery Vol. 46; no. 3; pp. 272 - 276
• Main Authors: Lim, Shi Yu Derek, Cheong, Ee Cherk, Oon, Hazel H
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Society of Plastic and Reconstructive Surgeons 01-05-2019; Thieme Medical Publishers, Inc; 대한성형외과학회
• Subjects: adalimumab; antibodies, monoclonal; Case Report; hidradenitis suppurativa; infliximab; tumor necrosis factor-alpha; 성형외과학; Antibodies, monoclonal; Tumor necrosis factor-alpha; Hidradenitis suppurativa; Infliximab; Adalimumab
• ISSN: 2234-6163; 2234-6171
• DOI: 10.5999/aps.2018.00339

Hidradenitis suppurativa (HS) is a chronic inflammatory follicular occlusive disease that involves the intertriginous areas. Treatment methods include conventional topical and systemic medication, radiotherapy, biologic agents, and surgical excision. Of late, there has been an increased focus on the use of biologic agents in patients with moderate to severe HS. Here, we present the case of a 46-year-old man with Hurley stage III HS for whom wide excision was ultimately curative, after aggressive medical therapy with the use of infliximab and adalimumab had succeeded in limiting the body surface area affected by the disease. This case demonstrates the effective treatment of severe HS with a combination of biologic therapy and surgery.